{"id":8704,"date":"2025-10-28T10:40:35","date_gmt":"2025-10-28T09:40:35","guid":{"rendered":"https:\/\/saniona.com\/?page_id=8704"},"modified":"2026-03-30T12:10:20","modified_gmt":"2026-03-30T10:10:20","slug":"san2668","status":"publish","type":"page","link":"https:\/\/saniona.com\/sv\/var-pipeline\/san2668\/","title":{"rendered":"SAN2668"},"content":{"rendered":"

[et_pb_section fb_built=”1″ fullwidth=”on” disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” disabled=”on” global_colors_info=”{}”][\/et_pb_section][et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”4.16″ _module_preset=”default” z_index=”1″ height=”56vh” height_tablet=”45vh” height_phone=”70vh” height_last_edited=”on|phone” global_colors_info=”{}”][et_pb_fullwidth_slider show_arrows=”off” use_bg_overlay=”off” admin_label=”Slider 03″ module_class=”home-slider-section single-pagebanner” _builder_version=”4.27.4″ _module_preset=”default” min_height=”56vh” min_height_tablet=”45vh” min_height_phone=”70vh” min_height_last_edited=”on|phone” animation_style=”fade” custom_css_slide_description=”animation-name: none;” global_colors_info=”{}”][et_pb_slide use_bg_overlay=”off” use_text_overlay=”off” admin_title=”Slider 01″ _builder_version=”4.21.0″ _module_preset=”default” header_level=”h6″ header_font=”Nunito Sans|600|on||||||” header_text_color=”#ffffff” header_font_size=”16px” header_line_height=”1.1em” body_font=”DM Serif Display||||||||” body_text_color=”#ffffff” body_font_size=”50px” body_line_height=”1.3em” background_enable_color=”off” background_image=”https:\/\/saniona.com\/wp-content\/uploads\/2021\/04\/saniona-san903.jpg” background_enable_image=”on” parallax=”on” button_alignment=”left” width=”92%” custom_padding=”180px||||false|false” custom_padding_tablet=”140px||||false|false” custom_padding_phone=”40px||||false|false” custom_padding_last_edited=”on|phone” header_text_color_tablet=”” header_text_color_phone=”#555758″ header_text_color_last_edited=”on|phone” body_font_size_tablet=”46px” body_font_size_phone=”40px” body_font_size_last_edited=”on|tablet” body_line_height_tablet=”54px” body_line_height_phone=”50px” body_line_height_last_edited=”on|tablet” background_last_edited=”on|phone” global_colors_info=”{}” sticky_transition=”on”]<\/p>\n

\n
V\u00c5R PIPELINE<\/a><\/h6>\n

SAN2668<\/p>\n<\/div>\n

[\/et_pb_slide][\/et_pb_fullwidth_slider][\/et_pb_section][et_pb_section fb_built=”1″ custom_padding_last_edited=”on|tablet” module_class=”flower-section” _builder_version=”4.16″ _module_preset=”default” background_color=”rgba(0,0,0,0)” custom_margin=”||||false|false” custom_padding=”14px||16px||false|false” custom_padding_tablet=”” custom_padding_phone=”” box_shadow_style=”preset3″ box_shadow_vertical=”-12px” box_shadow_spread=”-12px” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”||5px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/saniona.com\/wp-content\/uploads\/2021\/01\/Saniona_icon_lg_ltblue_new.png” alt=”Saniona Icon blue” title_text=”Saniona_icon_lg_ltblue_new” align_tablet=”” align_phone=”” align_last_edited=”on|phone” disabled_on=”on|off|off” _builder_version=”4.18.0″ _module_preset=”default” z_index=”-1″ width=”66%” width_tablet=”72%” width_phone=”” width_last_edited=”on|tablet” custom_margin=”-350px||-300px||false|false” custom_margin_tablet=”-280px||-300px||false|false” custom_margin_phone=”” custom_margin_last_edited=”on|tablet” filter_opacity=”70%” animation_style=”fade” animation_direction=”bottom” animation_duration=”1400ms” animation_delay=”200ms” scroll_rotating_enable=”on” scroll_rotating=”60|84|84|100|0\u00b0|30\u00b0|90\u00b0” module_alignment_tablet=”left” module_alignment_phone=”left” module_alignment_last_edited=”on|tablet” scroll_rotating_tablet=”65|84|84|100|0\u00b0|15\u00b0|90\u00b0” scroll_rotating_phone=”” scroll_rotating_last_edited=”on|tablet” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”rgba(0,0,0,0)” z_index=”60″ custom_padding=”16px||55px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”2_5,3_5″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”2_5″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_text_color=”#1d7ecd” header_font_size=”48px” header_line_height=”1.2em” custom_margin=”||0px|||” header_font_size_tablet=”38px” header_font_size_phone=”32px” header_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

SAN2668<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_text_color=”#1d7ecd” header_font_size=”48px” header_line_height=”1.2em” header_2_font=”Nunito Sans||||||||” header_2_text_color=”#1d7ecd” header_2_font_size=”30px” header_2_line_height=”1.2em” header_font_size_tablet=”38px” header_font_size_phone=”32px” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”” header_2_font_size_phone=”24px” header_2_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

En potentiell f\u00f6rst-i-klassen-behandling f\u00f6r sv\u00e5ra pediatriska epilepsier<\/h2>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”3_5″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”20px” text_line_height=”1.4em” custom_margin=”14px|||||” text_font_size_tablet=”” text_font_size_phone=”18px” text_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

SAN2668 \u00e4r Sanionas ledande kliniska l\u00e4kemedelskandidat f\u00f6r behandling av sv\u00e5ra epilepsier hos barn, inklusive utvecklingsrelaterade epileptiska encefalopatier (Developmental and Epileptic Encephalopathies, DEEs). Dessa syndrom \u00e4r ofta l\u00e4kemedelsresistenta, saknar godk\u00e4nda behandlingar och har livsl\u00e5nga konsekvenser f\u00f6r b\u00e5de patienter och deras familjer.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”rgba(150,199,240,0.3)” background_enable_image=”off” background_size=”contain” background_position=”top_right” custom_padding=”14px||6px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#1d7ecd” header_3_text_color=”#174d69″ header_3_font_size=”48px” header_3_line_height=”1.1em” header_3_font_size_tablet=”” header_3_font_size_phone=”40px” header_3_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

SAN2668<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_enable_color=”off” background_enable_image=”off” background_size=”contain” background_position=”top_right” custom_padding=”32px||45px||false|false” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px|||||” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”18px” text_line_height=”1.4em” min_height=”137px” custom_margin=”20px|||||” custom_padding=”||5px|||” global_colors_info=”{}”]<\/p>\n

SAN2668 \u00e4r utformad med selektiv farmakologi som riktar sig mot alla GABAA-receptorsubtyper som \u00e4r involverade i kontroll av epileptiska anfall. Detta m\u00f6jligg\u00f6r ett precist angreppss\u00e4tt f\u00f6r att f\u00f6rebygga anfall, samtidigt som risken f\u00f6r toleransutveckling, sedering, kognitiv p\u00e5verkan och motoriska biverkningar minimeras. Profilen st\u00f6djer potentialen f\u00f6r b\u00e4sta m\u00f6jliga effekt i sin klass f\u00f6r barn med sv\u00e5rbehandlade epilepsisyndrom.<\/p>\n

SAN2668 \u00e4r p\u00e5 v\u00e4g mot fas 1-studier under 2026. F\u00f6rutom s\u00e4kerhet och tolerabilitet kommer de planerade kliniska bed\u00f6mningarna att inkludera farmakodynamiska studier och analyser av m\u00e5lmolekylers aktivering, f\u00f6r att tidigt validera verkningsmekanismen och l\u00e4kemedlets f\u00f6rm\u00e5ga att uppn\u00e5 terapeutiska niv\u00e5er av receptorbindning som \u00e4r kopplade till stark anti-epileptisk effekt. Dessa data kommer att ligga till grund f\u00f6r ett rationellt dosval inf\u00f6r fas 2, med m\u00e5let att uppn\u00e5 en optimal balans mellan effekt och tolerabilitet hos barn.<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”18px” text_line_height=”1.4em” min_height=”137px” custom_margin=”20px|||||” custom_padding=”||5px|||” global_colors_info=”{}”]<\/p>\n

Programmet speglar Sanionas engagemang f\u00f6r att utveckla banbrytande jonkanalsmodulatorer f\u00f6r s\u00e4llsynta och sv\u00e5ra sjukdomar inom det centrala nervsystemet.<\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font_size=”18px” text_line_height=”1.5em” header_5_font=”Nunito Sans|800|||||||” header_5_text_color=”#ffffff” header_5_font_size=”22px” header_5_letter_spacing=”2px” background_color=”#ffc13f” custom_padding=”36px|50px|36px|30px|false|false” border_radii=”on|20px|20px|20px|20px” global_colors_info=”{}”]<\/p>\n

STATUS F\u00d6R SAN2668<\/h5>\n

SAN2668 \u00e4r p\u00e5 v\u00e4g mot fas 1-studier under 2026<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

V\u00c5R PIPELINE SAN2668 SAN2668En potentiell f\u00f6rst-i-klassen-behandling f\u00f6r sv\u00e5ra pediatriska epilepsierSAN2668 \u00e4r Sanionas ledande kliniska l\u00e4kemedelskandidat f\u00f6r behandling av sv\u00e5ra epilepsier hos barn, inklusive utvecklingsrelaterade epileptiska encefalopatier (Developmental and Epileptic Encephalopathies, DEEs). Dessa syndrom \u00e4r ofta l\u00e4kemedelsresistenta, saknar godk\u00e4nda behandlingar och har livsl\u00e5nga konsekvenser f\u00f6r b\u00e5de patienter och deras familjer.SAN2668SAN2668 \u00e4r utformad med selektiv farmakologi som […]<\/p>\n","protected":false},"author":7,"featured_media":4139,"parent":3689,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8704","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/pages\/8704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/comments?post=8704"}],"version-history":[{"count":0,"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/pages\/8704\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/pages\/3689"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/media\/4139"}],"wp:attachment":[{"href":"https:\/\/saniona.com\/sv\/wp-json\/wp\/v2\/media?parent=8704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}